COMMUNIQUÉS West-GlobeNewswire

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

28/04/2025 - 14:00

Presentations at WHS and SAWC to highlight EscharEx’s mechanism of action, preclinical advantages over SANTYL ® , and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs and support [...]

Quanta Therapeutics Presents Late-Breaking Data for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025

28/04/2025 - 14:00

- Preclinical data demonstrates synergy of QTX3544 with EGFR inhibitors, broadly enhancing anti-tumor activity - - Data supports ongoing Phase 1 clinical trial for QTX3544 as monotherapy and in combination with [...]

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

28/04/2025 - 14:00

Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN [...]

Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

28/04/2025 - 14:00

DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”) , a global leader in innovations for active healing, today announced that it will report financial results for [...]

Alignment Healthcare to Present at the BofA Securities Healthcare Conference

28/04/2025 - 14:00

ORANGE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the BofA Securities Healthcare Conference on Wednesday, May 14, at 2:20 p.m. PDT. A [...]

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

28/04/2025 - 14:00

-- PCRX-201 demonstrated two years of clinically meaningful improvements in pain, stiffness and function across all structural severity subgroups, including advanced disease -- -- Study Findings Presented at 2025 OARSI [...]

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

28/04/2025 - 14:00

Acquisition of approximately 71% stake in Kokomodo Ltd. Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.’s ability to craft real, controlled, climate-resilient cacao using [...]

ImPact Biotech Presents Updated Efficacy Data from Evaluation of Padeliporfin VTP in LG UTUC and Intermediate-Risk Prostate Cancer at AUA 2025

28/04/2025 - 14:00

– Complete response (CR) observed in 79% (26/33) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) of the ENLIGHTED Phase 3 trial evaluating [...]

Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis

28/04/2025 - 14:00

Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain metastases from solid tumors of different origins Underscores Radiopharm’s commitment to developing transformative oncology [...]

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025

28/04/2025 - 14:00

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025 Glasgow, Scotland – 28 April 2025. EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in [...]

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

28/04/2025 - 14:00

NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative [...]

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

28/04/2025 - 14:00

CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy [...]

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

28/04/2025 - 14:00

- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and [...]

DLH to Announce Fiscal 2025 Second Quarter Financial Results

28/04/2025 - 14:00

ATLANTA, April 28, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

28/04/2025 - 14:00

New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers Further Confirms the [...]

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

28/04/2025 - 14:00

VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a company focused on developing highly selective 5-HT2 [...]

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

28/04/2025 - 14:00

80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidates The data underscores the precision of Evaxion’s [...]

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

28/04/2025 - 14:01

BERKELEY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today [...]

Transactions in Connection with Share Buy-back Program

28/04/2025 - 14:16

Company Announcement COPENHAGEN, Denmark; April 28, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce [...]